8-K
filed May 29, 2026, 10:15 AM ET
CIK 0001999855
other material
confidence high
sentiment neutral
materiality 0.50
Carvana closes 2026-P2 auto ABS; issues multiple note classes, retains 5% for risk retention
Carvana Auto Receivables Trust 2026-P2
- Closed auto ABS trust 2026-P2 on May 27, issuing Classes A-1 through D, N ($16.5M), and XS notes.
- Issued beneficial interest certificates (100,000 units); 5% of certificates and Class N notes retained by Carvana.
- Notes sold to QIBs under Rule 144A; proceeds used to purchase auto loan receivables from Carvana and Carvana FAC.
- Transaction involves 12 agreements including receivables purchase, indenture, servicing by Bridgecrest Credit Company.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001770373-26-000029
- form_type
- 8-K
- ticker
- null
- cik
- 0001999855
- company_name
- Carvana Auto Receivables Trust 2026-P2
- filed_at
- 2026-05-29T14:15:42+00:00
- discovered_at
- 2026-05-29T14:17:00.219585+00:00
- generated_at
- 2026-05-29T14:17:54.104734+00:00
- sec_items
- ["1.01", "8.01", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.5
- calibrated_materiality_score
- 0.5
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001770373-26-000029
- json_url
- https://secwatch.observer/filing/0001770373-26-000029.json
- markdown_url
- https://secwatch.observer/filing/0001770373-26-000029.md
- text_url
- https://secwatch.observer/filing/0001770373-26-000029.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1999855/000177037326000029/0001770373-26-000029-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1770373/000177037326000029/crvna2026-p2xform8xkreclos.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
CPSH
CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share
CPS TECHNOLOGIES CORP/DE/
June 1, 2026, 9:35 AM ET
other_material
Items 1.01, 5.03, 8.01, 9.01
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
CLIR
ClearSign Technologies prices 777,780-share public offering at $4.33/share for ~$3.37M gross proceeds
ClearSign Technologies Corp
June 1, 2026, 8:30 AM ET
other_material
Items 1.01, 8.01, 9.01
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
RDAC
Shareholders approve SPAC extension to Oct 15, 2027; ~1.9M shares redeemed
Rising Dragon Acquisition Corp.
June 1, 2026, 6:08 AM ET
other_material
Items 1.01, 5.03, 5.07, 8.01, 9.01
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
SYRE
Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030
Spyre Therapeutics, Inc.
June 1, 2026, 4:01 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
ORKA
Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030
Oruka Therapeutics, Inc.
June 1, 2026, 4:01 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
VIASP
Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends
Via Renewables, Inc.
June 1, 2026, 3:06 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
BUKS
CEO Christopher Reedy discloses ongoing cancer treatment; remains in role
BUTLER NATIONAL CORP
June 1, 2026, 12:41 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
ONCY
Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned
ONCOLYTICS BIOTECH INC
June 1, 2026, 9:06 AM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.